A recent study found that antiretroviral therapy adherence below 90% was associated with significantly lower odds of viral suppression among women living with HIV. Researchers analyzed data from ...

High stigma levels correlate with lower ART adherence and viral suppression in women with HIV, especially those who inject drugs. The study used data from the WIHS, focusing on stigma's impact on HIV ...

This study assessed longitudinal relationships between patient healthcare empowerment, engagement in care, and viral control in the Women's Interagency HIV Study, a prospective cohort study of U.S.

In the early 1980s, as a physician at the University of California Medical Center, researching and treating sexually transmitted viral diseases, I found myself at the epicenter of an emerging crisis ...

Long-acting injectable antiretroviral treatment can improve medication adherence in patients who struggle with regularly taking daily pills, according to research presented at the Association of ...

GSK’s long-acting HIV regimen Cabenuva has already shown it works as well as daily oral therapies in patients who have the virus under control. Now, the injection has beaten daily drugs in individuals ...

To provide a forum and platform for investigators interested in HIV related adherence research to communicate and exchange skills and expertise in support of each other. To make investigators aware of ...

Recently incarcerated individuals with HIV face challenges in achieving sustained viral suppression (SVS) due to social conditions and health care access issues. Younger age, recent release, and ...

HIV patients demonstrated greater adherence to their antiretroviral therapy (ART) following the use of a low-cost educational VR application, according to a new study published in the Interactive ...

It is not clear what effect socioeconomic factors have on adherence to antiretroviral therapy (ART) among patients in low- and middle-income countries. We performed a systematic review of the ...

Researchers from the HIV Prevention Trials Network (HPTN) presented results from HPTN 091 ("I Am Study") at the HIVR4P 2024 conference in Lima, Peru. The study examined the acceptability and ...

Estimating benefit from dose dense adjuvant chemotherapy for early breast cancer in the PANTHER randomized phase 3 trial. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...